- Home
- KNSA
as 07-26-2024 4:00pm EST
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
| Founded: | 2015 | Country: | Bermuda |
| Employees: | N/A | City: | HAMILTON |
| Market Cap: | 1.4B | IPO Year: | 2018 |
| Target Price: | $32.00 | AVG Volume (30 days): | 704.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.12 - $27.88 | Next Earning Date: | 07-23-2024 |
| Revenue: | $338,930,000 | Revenue Growth: | 20.69% |
| Revenue Growth (this year): | 47.27% | Revenue Growth (next year): | 37.65% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Mar 7 '24 | Sell | $21.02 | 65,012 | $1,366,552.24 | 0 | SEC Form 4 |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Mar 4 '24 | Sell | $21.31 | 9,406 | $200,441.86 | 73,930 | SEC Form 4 |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Mar 4 '24 | Sell | $22.00 | 3,336 | $73,392.00 | 70,594 | SEC Form 4 |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Mar 4 '24 | Sell | $21.00 | 5,582 | $117,222.00 | 65,012 | SEC Form 4 |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Mar 1 '24 | Sell | $21.77 | 18,844 | $410,233.88 | 44,892 | SEC Form 4 |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Mar 1 '24 | Sell | $22.03 | 1,189 | $26,193.67 | 122,847 | SEC Form 4 |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Feb 28 '24 | Sell | $21.79 | 5,126 | $111,695.54 | 17,588 | SEC Form 4 |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Feb 28 '24 | Sell | $21.45 | 9,659 | $207,185.55 | 17,588 | SEC Form 4 |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Feb 27 '24 | Sell | $21.03 | 10,156 | $213,580.68 | 44,892 | SEC Form 4 |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Jan 3 '24 | Sell | $20.00 | 12,000 | $240,000.00 | 15,632 | SEC Form 4 |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Jan 2 '24 | Sell | $19.17 | 16,670 | $319,563.90 | 17,005 | SEC Form 4 |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Dec 19 '23 | Sell | $19.13 | 9,316 | $178,215.08 | 17,005 | SEC Form 4 |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Dec 7 '23 | Sell | $17.54 | 7,380 | $129,445.20 | 66,112 | SEC Form 4 |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Dec 7 '23 | Sell | $17.64 | 13,017 | $229,619.88 | 53,095 | SEC Form 4 |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Dec 7 '23 | Sell | $17.75 | 6,702 | $118,960.50 | 46,393 | SEC Form 4 |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Dec 7 '23 | Sell | $17.81 | 1,501 | $26,732.81 | 44,892 | SEC Form 4 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
Zacks
9 hours ago
Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know
MT Newswires
12 hours ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $3,491,947, According to a Recent SEC Filing
Zacks
12 hours ago
Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why
MT Newswires
12 hours ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $601,108, According to a Recent SEC Filing
MT Newswires
13 hours ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $578,966, According to a Recent SEC Filing
Simply Wall St.
3 days ago
Kiniksa Pharmaceuticals International And Two More Firms Possibly Priced Below Market Value Estimates
MT Newswires
3 days ago
Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $34 From $30, Maintains Outperform Rating
Zacks
4 days ago
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.